Innate Pharma acquires anti-C5aR antibody from Novo Nordisk

19:00 EDT 4 Jun 2017 | Pharmaceutical Technology

French biotechnology company Innate Pharma has signed an agreement to acquire a clinical-stage anti-C5a receptor (C5aR) antibody (IPH5401) from Danish pharmaceutical firm Novo Nordisk for €40m.

Original Article: Innate Pharma acquires anti-C5aR antibody from Novo Nordisk


More From BioPortfolio on "Innate Pharma acquires anti-C5aR antibody from Novo Nordisk"

Quick Search

Relevant Topics

Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...